Financial Daily from THE HINDU group of publications
Wednesday, Aug 03, 2005


News
Features
Stocks
Port Info
Archives
Google

Group Sites

Industry & Economy - Pharmaceuticals


Prices of almost all life-saving drugs unchanged: Paswan

Our Bureau

New Delhi , Aug. 2

PUTTING to rest concerns about steep increase in prices of essential drugs, the Chemicals and Fertilisers Minister, Mr Ram Vilas Paswan, today told the Lok Sabha that prices of most of the life-saving drugs have remained unchanged.

In a response to a motion moved by Mr Ajoy Chakraborty (CPI) and some other members, Mr Paswan quoted the ORG-IMS monthly report for May 2005 according to which, only 833 (2.73 per cent) medicines out of 30,485 drugs analysed had increased while the cost of 245 (0.81 per cent) had declined.

"The prices of 29,407 (96.46 per cent) had remained the same, in most cases price increases were well within reasonable limits," Mr Paswan said.

Also, the percentage change in the Wholesale Price Index for drugs and medicines is less than that for all commodities during the last five years, he added.

On the steps taken to contain the price hike, Mr Paswan said that the Government had set up a Committee last year to examine the span of price control including trade margins. This Committee has recommended "intensive monitoring" of prices of all those drugs out of the select basket (National List of Essential Medicines, 2003) which are not under price control, he said.

Elaborating on this, Mr Paswan said that the Committee has also recommended ceilings on trade margins of drugs, a system of price negotiations for new patented drugs, special schemes for people below poverty line, introduction of Rajasthan model for bulk purchase of medicines directly from the manufacturer and selling them at reduced prices.

The Committee had also recommended compounding of offences under the Essential Commodities Act, establishment of First Schedule of Drugs (Prices Control) Order, 1995 cells in all states on the Karnataka model, price negotiations at the time of launching of a new patented drug and increasing public awareness.

The National Pharmaceutical Pricing Authority (NPPA) had also asked companies the reasons for steep price rise and about 18 of them have reduced prices voluntarily in respect of 29 formulation packs ranging between 1.15 per cent and 34.62 per cent.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
Water storage level 25 pc higher than average in a decade — Oil seeds, rice coverage still lagging behind


New low-pressure area advanced by a day
2 more Vizag sugar factories plan to start co-generation
Supplementary demand for grants placed in LS
`Govt keen to continue fiscal consolidation efforts'
Youth rescued from rare cancer caused by prevalent bacteria
Talks on for Rs 2,000-cr DFID aid for AP
CAG report faults Bengal power, fisheries PSUs
Under-recoveries by oil cos may exceed Rs 40,000 cr: Aiyar
`ONGC, GAIL, Reliance allowed to market LPG'
Iranian team to discuss gas pipeline project today
Prices of almost all life-saving drugs unchanged: Paswan
Govt issues instructions on service tax changes
`Corporate India must see tax as board level issue'
Move to streamline technical education in AP
British education initiative
HSBC to sell prime properties through e-auction
Setting up effluent plants is Tirupur units' new dilemma
Divestment's good economics, says Chidambaram
NGO fund for rehabilitating tribals hit by Posco project
PM calls for strengthening knowledge base
Kerala to export procured pepper
REL announces Rs 100-cr disaster management plan — To restore supply within 24 hours
IA, Air India to operate normal schedules from today
Even bank vaults, currency chests not spared
Normalcy returns to Mumbai
Mumbai rain claims at 10,000 for Rs 1,500 cr
Rains wreak havoc — Maharashtra poultry industry in trouble
Kurla shopowners bear the brunt of floods
Agriculture Board ensures supply of vegetables in Mumbai
Eco-tourism projects for Kollam district


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line